K-EXIT POUDRE DIN 00765252
Status: Cancelled Post Market
Holder: OMEGA LABORATORIES LIMITED
Molecule: SODIUM POLYSTYRENE SULFONATE
Health Canada record
| Active ingredient(s) | SODIUM POLYSTYRENE SULFONATE 100 % |
|---|---|
| Dosage form | Powder For Solution |
| Route | Oral; Rectal |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | V03AE01 POLYSTYRENE SULPHONATE |
| Original market date | 31-Dec-1988 |
| Current status date | 20-Jun-2022 |
| Source | Health Canada DPD |
Establishment licence of the holder
Omega Laboratories Ltd. (now Juno Pharma Canada Inc.) — licence 100277, not currently licensed, last inspection rating C (2025-05-20).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing SODIUM POLYSTYRENE SULFONATE
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02497557 | JAMP SODIUM POLYSTYRENE SULFONATE | JAMP PHARMA CORPORATION | Powder For Suspension | SODIUM POLYSTYRENE SULFONATE 1 G | Marketed |
| 02569701 | JAMP SODIUM POLYSTYRENE SULFONATE | JAMP PHARMA CORPORATION | Suspension | SODIUM POLYSTYRENE SULFONATE 250 MG | Approved |
| 02026961 | KAYEXALATE | SANOFI-AVENTIS CANADA INC | Powder For Suspension | SODIUM POLYSTYRENE SULFONATE 1 G | Marketed |
| 02473968 | ODAN-SODIUM POLYSTYRENE SULFONATE | ODAN LABORATORIESLTD | Suspension | SODIUM POLYSTYRENE SULFONATE 250 MG | Marketed |
| 02473941 | ODAN-SODIUM POLYSTYRENE SULFONATE | ODAN LABORATORIESLTD | Powder For Suspension | SODIUM POLYSTYRENE SULFONATE 1 G | Marketed |
| 02501872 | PMS-SODIUM POLYSTYRENE SULFONATE | PHARMASCIENCE INC | Suspension | SODIUM POLYSTYRENE SULFONATE 250 MG | Approved |
| 02501864 | PMS-SODIUM POLYSTYRENE SULFONATE | PHARMASCIENCE INC | Powder For Suspension | SODIUM POLYSTYRENE SULFONATE 1 G | Approved |
| 00755338 | SOLYSTAT | PENDOPHARM DIVISION OF PHARMASCIENCE INC | Powder For Suspension | SODIUM POLYSTYRENE SULFONATE 1 G | Marketed |
| 00769541 | SOLYSTAT | PENDOPHARM DIVISION OF PHARMASCIENCE INC | Suspension | SODIUM POLYSTYRENE SULFONATE 250 MG | Marketed |
| 02261650 | PHL-SODIUM POLYSTYRENE SULFONATE ORAL SUSPENSION | PHARMEL INC | Suspension | SODIUM POLYSTYRENE SULFONATE 250 MG | Cancelled Post Market |
| 02261677 | PHL-SODIUM POLYSTYRENE SULFONATE POWDER | PHARMEL INC | Powder | SODIUM POLYSTYRENE SULFONATE 94.3 MG | Cancelled Post Market |
| 02261669 | PHL-SODIUM POLYSTYRENE SULFONATE RETENTION ENEMA | PHARMEL INC | Suspension | SODIUM POLYSTYRENE SULFONATE 250 MG | Cancelled Post Market |
| 00769533 | SOLYSTAT | PENDOPHARM DIVISION OF PHARMASCIENCE INC | Suspension | SODIUM POLYSTYRENE SULFONATE 250 MG | Cancelled Post Market |
| 00722456 | SPS SUSPENSION 15GM/60ML | CAROLINA MEDICAL PRODUCTS COMPANY | Suspension | SODIUM POLYSTYRENE SULFONATE 15 G | Cancelled Post Market |
International API supply for SODIUM POLYSTYRENE SULFONATE
1 valid EDQM Certificates of Suitability from 1 holders. 4 active FDA Drug Master Files.
Request a quote for K-EXIT POUDRE